Aaron Cohn, MD
Ophthalmology · Media, PANPI 1952517435
Payments from drug & device makers
Across 148 payments — averaging $135.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Rxsight Inc$4K
- Alcon$2K
- Sight Sciences, Inc.$343
- Johnson & Johnson Surgical Vision, Inc.$271
- Glaukos Corporation$208
- plus $467 from 13 others
Across 1 payment — averaging $16.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$17
What the payments were for
- Consulting fees$3,79547%
- Speaking & faculty fees$3765%
- Food & beverage$3,81548%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $12,578 |
| Rxsight Inc | 6 | $4,071 |
| Alcon | 85 | $2,047 |
| Sight Sciences, Inc. | 8 | $343 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $271 |
| Glaukos Corporation | 3 | $208 |
| Amgen | 5 | $96 |
| Ivantis, Inc | 3 | $68 |
| Dompe US, Inc. | 2 | $67 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| NEW World Medical,inc. | 1 | $34 |
| Carl Zeiss Meditec, Inc. | 2 | $31 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Omeros Corporation | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Thea Pharma Inc. | 1 | $14 |
| Iridex Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$3,933
- RXSIGHT INJECTOR CARTRIDGE$3,933
- LIGHT ADJUSTABLE LENS (LAL)$3,933
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,933
- RXSIGHT INJECTOR HANDPIECE$3,933
- Clareon$330
- iStent inject W$128
- OMNI$125
- XEN GLAUCOMA TREATMENT SYSTEM$114
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$112
- OMNI(R) SURGICAL SYSTEM (US)$107
- XEN$100
How this compares
$19,985 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 96 | $49,458 |
| LumiganBimatoprost | 96 | $41,071 |
| CombiganBrimonidine Tartrate/Timolol | 69 | $20,554 |
| RhopressaNetarsudil Mesylate | 33 | $20,101 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 120 | $19,850 |
| Latanoprost | 989 | $11,454 |
| VyzultaLatanoprostene Bunod | 27 | $11,247 |
| Prednisolone Acetate | 265 | $9,166 |
| Timolol Maleate | 191 | $3,974 |
| AzoptBrinzolamide | 11 | $3,967 |
| Travoprost | 16 | $3,769 |
| Acetazolamide | 22 | $3,044 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 185 | $2,738 |
| Ketorolac Tromethamine | 199 | $2,245 |
| Brimonidine Tartrate | 117 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $15 | $69,560129 claims |
| AbbVieLumigan, Combigan | $12,578 | $61,625165 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $24 | $11,24727 claims |
| AlconAzopt | $2,047 | $3,96711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Media
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.